dex

Phase 2Small molecule

SSeoul National University Hospital

dex is one of 38 small molecule programs targeting Total Hip Arthroplasty. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Hip ArthroplastyActive, not recruiting

Total Hip ArthroplastyPhase 2

Active, not recruiting

Competition

Competitive Landscape

101 competitors in Total Hip Arthroplasty

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

1 2

Toradol

Roche

Approved

1 3

Naropin

FFresenius Kabi Oncology Ltd.

Approved

9 4

Medrol

Pfizer

Approved

1 5

Decadron

AAspen Global Incorporated

Approved

5 6

Marcaine

IInnocoll

Approved

5 7

Xylocaine

MMEDRx USA, Inc.

Approved

4 8

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 9

Advil

KKenvue Brands

Approved

1 10

Oxycontin

PProtega

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dexamethasone1 trial

Interscalene Nerve Blocks With Ropivacaine Alone, With Dexamethasone, Plus Systemic Dexamethasone

Terminated·TThe Cleveland Clinic·N/A·NCT00519584·218 enrolled

Total Hip Arthroplasty1 trial

Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty

Completed·YYale University·Phase 2·NCT03977454·192 enrolled

Postoperative Analgesia1 trial

Rectal Dexmedetomidine Niosomes for Postoperative Analgesia in Pediatric Cancer Patients.

Unknown status·—·Phase 2/3·NCT05340725·45 enrolled

Dexmedetomidine1 trial

Dexmedetomidine for Catheter-related Bladder Discomfort

Unknown status·SSeoul National University Hospital·Phase 4·NCT01991223·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for dex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSeoul National University Hospital

dex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dexamethasone1 trial

Total Hip Arthroplasty1 trial

Postoperative Analgesia1 trial

Dexmedetomidine1 trial

References

Drug Info

Quick Facts

Related News